文献速递湿疹皮炎与荨麻疹

QY201口服双靶点抑制剂治疗中重度特应性皮炎2期剂量探索试验

Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
PubMed 文献 · J Am Acad Dermatol · 2026-10-20

这项多中心、随机、双盲、安慰剂对照2期试验纳入200例中重度特应性皮炎成人患者,按1:1:1:1随机接受QY201 5mg、10mg或20mg每日两次或安慰剂治疗12周。主要终点第12周EASI-75应答率在5mg、10mg、20mg组分别为72.9%、84.7%和81.4%,安慰剂组为18.5%(均P<0.0001)。不良事件多为轻中度,结果支持10mg和20mg每日两次剂量进入3期确认性试验。

要点

  • IGA应答率在10mg和20mg组分别为64.3%和71.3%,安慰剂组为12.4%。
  • 不良事件发生率随剂量升高,但多为轻中度,支持10mg和20mg剂量进一步研究。

核心结论

  • QY201 10mg和20mg每日两次在中重度特应性皮炎成人患者中显示显著疗效,支持进入3期确认性试验。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2期剂量探索试验,纳入200例中重度特应性皮炎成人患者。
  • 患者按1:1:1:1随机接受QY201 5mg、10mg或20mg每日两次或安慰剂治疗12周。

主要发现

  • 第12周EASI-75应答率在5mg、10mg、20mg组分别为72.9%、84.7%和81.4%,安慰剂组为18.5%(均P<0.0001)。
  • 第12周IGA应答率在5mg、10mg、20mg组分别为44.7%(P=0.0011)、64.3%(P<0.0001)和71.3%(P<0.0001),安慰剂组为12.4%。
  • 治疗中出现的不良事件发生率在5mg、10mg、20mg组分别为74.0%、75.5%和90.4%,安慰剂组为69.4%,大多为轻中度。

关键数值与推荐

  • 主要终点为第12周达到EASI-75(湿疹面积和严重度指数改善≥75%)的患者比例。

临床怎么用

  • 2期结果提示10mg和20mg每日两次为后续3期试验的候选剂量。

局限性

  • 随访时间短且为单一国家人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: QY201 is a novel oral Janus kinase 1 and tyrosine kinase 2 inhibitor. OBJECTIVE: To evaluate the efficacy of multiple QY201 doses in moderate-to-severe atopic dermatitis (AD), and to inform dose selection for phase 3 studies. METHODS: In this phase 2, randomized, double-blind, placebo-controlled trial, 200 adults with moderate-to-severe AD were randomized 1:1:1:1 to receive QY201 (5 mg, 10 mg, or 20 mg twice daily [BID]) or placebo for 12 weeks. The primary endpoint was the proportion of patients achieving ≥75% improvement in Eczema Area and Severity Index (EASI-75) at week 12. RESULTS: EASI-75 response rates at week 12 were 72.9%, 84.7% and 81.4% in the 5 mg BID, 10 mg BID, and 20 mg BID groups, respectively, compared with 18.5% in the placebo group (all P<0.0001). Investigator's Global Assessment response rates were 44.7% (P=0.0011), 64.3% (P<0.0001), and 71.3% (P<0.0001), respectively, versus 12.4% with placebo. Treatment-emergent adverse events occurred in 74.0%, 75.5%, and 90.4% of patients receiving QY201, compared to 69.4% with placebo; most were mild or moderate. LIMITATIONS: Short follow-up and single-country population. CONCLUSION: The phase 2 findings support further evaluation of QY201 at doses of 10 mg BID and 20 mg BID in confirmatory phase 3 trials.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang T, Li J, Liang Y, et al. Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial. J Am Acad Dermatol. 2026. PMID: 42901423. doi:10.1016/j.jaad.2026.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。